Lindfors Nina, Geurts Jan, Drago Lorenzo, Arts J J, Juutilainen Vesa, Hyvönen Pekka, Suda Arnold J, Domenico Aloj, Artiaco Stefano, Alizadeh Chingiz, Brychcy Adrian, Bialecki Jertzy, Romanò Carlo L
Department of Orthopaedic and Plastic Surgery, Helsinki University Central Hospital, Helsinki University, Helsinki, Finland.
Department of Orthopaedic Surgery, Research School CAPHRI, Maastricht University Medical Centre, Maastricht, The Netherlands.
Adv Exp Med Biol. 2017;971:81-92. doi: 10.1007/5584_2016_156.
Osteomyelitis is an infectious process in bone that occasionally leads to bone destruction. Traditionally, the surgical treatment procedure is performed in combination with systemic and local antibiotics as a two-stage procedure that uses autograft or allograft bone for filling of the cavitary defect. Bioactive glass (BAG-S53P4) is a bone substitute with proven antibacterial and bone bonding properties.One hundred and sixteen patients who had verified chronic osteomyelitis was treated using BAG-S53P4 as part of the treatment. Most of the patients had previously undergone numerous procedures, sometimes for decades. A register of patient data obtained from 11 centers from Finland, Italy, the Netherlands, Germany, Azerbaijan and Poland was set-up and continuously maintained at Helsinki University Central Hospital.The location of the osteomyelitis was mainly in the tibia followed by the femur and then the calcaneus. The median age of the patients was 48 years (15-87). The patients were either treated according to a one-stage procedure without local antibiotics (85 %) or by a two-stage procedure using antibiotic beads in the first procedure (15 %). The minimum follow-up was 1 year (12-95 months, median 31).The cure rate was 104/116, the total success rate 90 % and most of the patients showed a rapid recovery.The study shows that (BAG-S53P4) can be used in a one-stage procedure in treatment of osteomyelitis with excellent results.
骨髓炎是一种发生在骨骼的感染性病变,偶尔会导致骨质破坏。传统上,外科治疗程序是与全身和局部使用抗生素相结合,作为一种两阶段的程序,使用自体骨或异体骨来填充空洞性缺损。生物活性玻璃(BAG-S53P4)是一种已被证实具有抗菌和骨结合特性的骨替代物。116例经证实患有慢性骨髓炎的患者接受了使用BAG-S53P4作为治疗一部分的治疗。大多数患者此前已经接受过多次手术,有时长达数十年。在赫尔辛基大学中心医院建立并持续维护了一个从芬兰、意大利、荷兰、德国、阿塞拜疆和波兰的11个中心获取的患者数据登记册。骨髓炎的发病部位主要在胫骨,其次是股骨,然后是跟骨。患者的中位年龄为48岁(15 - 87岁)。患者要么按照不使用局部抗生素的单阶段程序进行治疗(85%),要么通过在第一阶段使用抗生素珠的两阶段程序进行治疗(15%)。最短随访时间为1年(12 - 95个月,中位时间31个月)。治愈率为104/116,总成功率为90%,大多数患者恢复迅速。该研究表明,(BAG-S53P4)可用于单阶段程序治疗骨髓炎,效果极佳。